Prothena Corp. (PRTA) announced after the bell Thursday that its Phase 1 study of PRX002, a potential treatment of Parkinson's disease, met its primary objective. The study showed that PRX002 leads to mean reduction of free serum alpha-synuclein levels of up to 96%. The stock is now up 10.77 on 321K shares.
Prothena gapped up slightly Thursday and rose further around midday. The stock closed higher by 0.75 at $29.23 on the highest volume in nearly a month.
For comments and feedback contact: editorial@rttnews.com
Business News